
Alumis Inc. is a precision medicines company with the mission to transform the lives of patients with autoimmune diseases. Even with treatment innovations of the last two decades, many patients with immunologic conditions continue to suffer - our goal is to fundamentally change the outcomes for these patients.
Alumis Inc. is a precision medicines company with the mission to transform the lives of patients with autoimmune diseases. Even with treatment innovations of the last two decades, many patients with immunologic conditions continue to suffer - our goal is to fundamentally change the outcomes for these patients.
Alumis is seeking an experienced Director of Thought Leader Liaison (TLL) with deep expertise in Dermatology. This role is a field-based commercial leadership role responsible for leading a team of field based TLLs, to develop and execute Key Opinion Leader (KOL) engagement strategies for the US launch of envudeucitinib for Psoriasis.
The successful candidate will be a key member of the brand marketing team, working across multiple stakeholders at the intersection of marketing, medical, and field execution, with accountability for team leadership, KOL strategy and execution, and strategic insight generation to shape brand strategy. This role will require a deep understanding of medical science, excellent leadership capabilities, and a strong ability to drive the success of cross-functional teams.
Alumis Inc. is an equal opportunity employer.
Alumis compensation packages include generous stock option grants for all employees as well as an annual bonus program. The salary range for this position is $215,000-$260,000 USD annually. This salary range is an estimate, and the actual salary may very based on the Company’s compensation practices degree and background.
Alumis compensation packages include generous stock option grants for all employees as well as an annual bonus program.
Other benefits include:
We are a hard-working, collaborative team on a mission to transform patient’s lives-- and we aspire to elevate, challenge and nurture one another along the way.

At Alumis, our goal is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies.
We recognize that patients living with immune-mediated diseases need alternatives to currently available therapies. Despite recent advances and innovations in the treatment of immune-mediated diseases, many patients continue to suffer, cycling through currently approved therapies while looking for a solution that alleviates the debilitating impact of their disease without life-limiting side effects.
Addressing the needs of these patients is why we exist. We are pioneering a precision approach that leverages insights we derive from powerful data analytics to select the right target, right molecule, right indication, right patient, and right endpoint resulting in optimized outcomes for patients. We believe that combining our insights with an integrated approach to drug development will produce the next generation of treatments to address immune dysfunction.
Incubated by Foresite Labs, Alumis is led by a team of deeply experienced professionals who are devoted to transforming the lives of patients with immune-mediated diseases by developing a pipeline of transformative therapies.